Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Contrast sensitivity impairment in drug-naïve Parkinson’s disease patients associates with early cognitive decline

Abstract

Objectives

To investigate the contrast sensitivity function in drug-naïve Parkinson’s disease (PD) patients and its predictive value with longitudinal follow-up data.

Methods

We included newly diagnosed non-demented PD patients who performed contrast sensitivity test between 2013 and 2014. Contrast sensitivity function at drug-naïve state in PD patients was compared with age-matched normal control data of our center. Correlation between contrast sensitivity function and parkinsonian motor and non-motor features including the Mini-Mental State Exam (MMSE) score at the time of diagnosis were analyzed by linear regression. With longitudinal follow-up data after initiating anti-parkinsonian therapy, the risk conferred on subsequent visual hallucinations and cognitive impairment requiring anti-dementia drugs was analyzed by dichotomizing PD group based on the initial contrast sensitivity function.

Results

Forty-eight patients were finally included, and mean follow-up periods were 43 months. Contrast sensitivity function in drug-naïve PD patients was significantly worse than controls. Contrast sensitivity function correlated with sleep disturbance (p = 0.001) and global cognitive status reflected by the MMSE score (p = 0.020). It also associated with further decline in the MMSE during the follow-ups (p = 0.029). Patients with below average contrast sensitivity function at the time of diagnosis showed higher risk of cognitive decline requiring anti-dementia drugs (adjusted odds ratio = 4.68, p = 0.04) and of visual hallucinations (adjusted odds ratio = 12.54, p = 0.04) than those above average function during the follow-up.

Conclusion

Contrast sensitivity impairment in drug-naïve PD patients associates with clinical demand for therapeutic intervention of cognitive decline as well as development of visual hallucinations in the early course of the disease.

This is a preview of subscription content, log in to check access.

Fig. 1

References

  1. 1.

    Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, Poewe W, Sampaio C, Stern MB, Dodel R, Dubois B, Holloway R, Jankovic J, Kulisevsky J, Lang AE, Lees A, Leurgans S, LeWitt PA, Nyenhuis D, Olanow CW, Rascol O, Schrag A, Teresi JA, van Hilten JJ, LaPelle N, Movement Disorder Society UPDRS Revision Task Force (2008) Movement Disorder Society-sponsored revision of the unified Parkinson’s disease rating scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord Off J Mov Disord Soc 23:2129–2170

  2. 2.

    Postuma RB, Aarsland D, Barone P, Burn DJ, Hawkes CH, Oertel W, Ziemssen T (2012) Identifying prodromal Parkinson’s disease: pre-motor disorders in Parkinson’s disease. Mov Disord 27:617–626

  3. 3.

    Chaudhuri KR, Healy DG, Schapira AH (2006) Non-motor symptoms of Parkinson’s disease: diagnosis and management. Lancet Neurol 5:235–245

  4. 4.

    Bodis-Wollner I (2009) Retinopathy in Parkinson disease. J Neural Transm 116:1493

  5. 5.

    Bulens C, Meerwaldt JD, van der Wildt GJ, Keemink CJ (1986) Contrast sensitivity in Parkinson’s disease. Neurology 36:1121–1125

  6. 6.

    Pieri V, Diederich NJ, Raman R, Goetz CG (2000) Decreased color discrimination and contrast sensitivity in Parkinson’s disease. J Neurol Sci 172:7–11. https://doi.org/10.1016/S0022-510X(99)00204-X

  7. 7.

    Price MJM, Feldman RG, Adelberg D, Kayne H (1992) Abnormalities in color vision and contrast sensitivity in Parkinson’s disease. Neurology. 42:887–890

  8. 8.

    Hutton JT, Morris JL, Elias JW (1993) Levodopa improves spatial contrast sensitivity in Parkinson’s disease. Arch Neurol 50:721–724

  9. 9.

    Jones RD, Donaldson IM, Timmings PL (1992) Impairment of high-contrast visual acuity in Parkinson’s disease. Mov Disord 7:232–238. https://doi.org/10.1002/mds.870070308

  10. 10.

    Arden GB (1978) The importance of measuring contrast sensitivity in cases of visual disturbance. Br J Ophthalmol 62:198–209

  11. 11.

    Ward ME, Gelfand JM, Lui L-Y, Ou Y, Green AJ, Stone K, Pedula KL, Cummings SR, Yaffe K (2018) Reduced contrast sensitivity among older women is associated with increased risk of cognitive impairment. Ann Neurol 83:730–738. https://doi.org/10.1002/ana.25196

  12. 12.

    Adam CR, Shrier E, Ding Y, Glazman S, Bodis-Wollner I (2013) Correlation of inner retinal thickness evaluated by spectral-domain optical coherence tomography and contrast sensitivity in Parkinson disease. J Neuroophthalmol 33:137–142. https://doi.org/10.1097/WNO.0b013e31828c4e1a

  13. 13.

    Diederich NJ, Goetz CG, Raman R, Pappert EJ, Leurgans S, Piery V (1998) Poor visual discrimination and visual hallucinations in Parkinson’s disease. Clin Neuropharmacol 21:289–295

  14. 14.

    Lee J-Y, Kim JM, Ahn J, Kim H-J, Jeon BS, Kim TW (2014) Retinal nerve fiber layer thickness and visual hallucinations in Parkinson’s disease. Mov Disord Off J Mov Disord Soc 29:61–67. https://doi.org/10.1002/mds.25543

  15. 15.

    Pesudovs K, Hazel CA, Doran RML, Elliott DB (2004) The usefulness of Vistech and FACT contrast sensitivity charts for cataract and refractive surgery outcomes research. Br J Ophthalmol 88:11–16. https://doi.org/10.1136/bjo.88.1.11

  16. 16.

    LeGates TA, Fernandez DC, Hattar S (2014) Light as a central modulator of circadian rhythms, sleep and affect. Nat Rev Neurosci 15:443–454. https://doi.org/10.1038/nrn3743

  17. 17.

    Hwang CK, Chaurasia SS, Jackson CR, Chan GC-K, Storm DR, Iuvone PM (2013) Circadian rhythm of contrast sensitivity is regulated by a dopamine-neuronal PAS-domain protein 2-adenylyl cyclase 1 signaling pathway in retinal ganglion cells. J Neurosci 33:14989–14997. https://doi.org/10.1523/JNEUROSCI.2039-13.2013

  18. 18.

    Niemeyer JE, Paradiso MA (2017) Contrast sensitivity, V1 neural activity, and natural vision. J Neurophysiol 117:492–508. https://doi.org/10.1152/jn.00635.2016

  19. 19.

    Elliott D, Whitaker D, MacVeigh D (1990) Neural contribution to spatiotemporal contrast sensitivity decline in healthy ageing eyes. Vis Res 30:541–547. https://doi.org/10.1016/0042-6989(90)90066-T

  20. 20.

    Ridder A, Müller MLTM, Kotagal V, Frey KA, Albin RL, Bohnen NI (2017) Impaired contrast sensitivity is associated with more severe cognitive impairment in Parkinson disease. Parkinsonism Relat Disord 34:15–19. https://doi.org/10.1016/j.parkreldis.2016.10.006

  21. 21.

    Moes E, Lombardi KM (2009) The relationship between contrast sensitivity, gait, and reading speed in Parkinson’s disease. Neuropsychol Dev Cogn B Aging Neuropsychol Cogn 16:121–132. https://doi.org/10.1080/13825580802233418

  22. 22.

    Satue M, Rodrigo MJ, Obis J, Vilades E, Gracia H, Otin S, Fuertes MI, Alarcia R, Crespo JA, Polo V, Larrosa JM, Pablo LE, Garcia-Martin E (2017) Evaluation of progressive visual dysfunction and retinal degeneration in patients with Parkinson’s disease. Investig Opthalmol Vis Sci 58:1151. https://doi.org/10.1167/iovs.16-20460

  23. 23.

    Polo V, Rodrigo MJ, Garcia-Martin E, Otin S, Larrosa JM, Fuertes MI, Bambo MP, Pablo LE, Satue M (2017) Visual dysfunction and its correlation with retinal changes in patients with Alzheimer’s disease. Eye. 31:1034–1041. https://doi.org/10.1038/eye.2017.23

  24. 24.

    Ortuño-Lizarán I, Beach TG, Serrano GE, Walker DG, Adler CH, Cuenca N (2018) Phosphorylated α-synuclein in the retina is a biomarker of Parkinson’s disease pathology severity. Mov Disord 33:1315–1324. https://doi.org/10.1002/mds.27392

  25. 25.

    Shah TM, Gupta SM, Chatterjee P, Campbell M, Martins RN (2017) Beta-amyloid sequelae in the eye: a critical review on its diagnostic significance and clinical relevance in Alzheimer’s disease. Mol Psychiatry 22:353–363. https://doi.org/10.1038/mp.2016.251

  26. 26.

    Lenka A, Hegde S, Jhunjhunwala KR, Pal PK (2016) Interactions of visual hallucinations, rapid eye movement sleep behavior disorder, and cognitive impairment in Parkinson’s disease: a review. Parkinsonism Relat Disord 22:1–8. https://doi.org/10.1016/j.parkreldis.2015.11.018

  27. 27.

    Fereshtehnejad S-M, Postuma RB (2017) Subtypes of Parkinson’s disease: what do they tell us about disease progression? Curr Neurol Neurosci Rep 17:34–10. https://doi.org/10.1007/s11910-017-0738-x

  28. 28.

    Kulisevsky J, Pagonabarraga J (2009) Cognitive impairment in Parkinson’s disease: tools for diagnosis and assessment. Mov Disord 24:1103–1110. https://doi.org/10.1002/mds.22506

  29. 29.

    Richman J, Spaeth GL, Wirostko B (2013) Contrast sensitivity basics and a critique of currently available tests. J Cataract Refract Surg 39:1100–1106. https://doi.org/10.1016/j.jcrs.2013.05.001

Download references

Funding

This work was supported by a National Research Foundation (NRF) grant funded by the Ministry of Education, Science and Technology (MEST) in Korea (NRF-2018R1C1B3008971) and by a clinical research grant-in-aid from the Seoul Metropolitan Government-Seoul National University (SMG-SNU) Boramae Medical Center (03–2015-8).

Author information

Correspondence to Jee-Young Lee.

Ethics declarations

Conflict of interests

SB Hong, J.-Y. Lee, J. Ahn, D Yoo, JY Shin, and B. Jeon report there are no potential conflict of interest related to this work.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Hong, S.B., Ahn, J., Yoo, D. et al. Contrast sensitivity impairment in drug-naïve Parkinson’s disease patients associates with early cognitive decline. Neurol Sci (2020). https://doi.org/10.1007/s10072-020-04289-6

Download citation

Keywords

  • Parkinson’s disease
  • Contrast sensitivity
  • Cognition